Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ)
CNY 2.31
(2.67%)
CNY 2.31
(2.67%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 650.66 Million CNY | -19.13% |
| 2022 | 804.56 Million CNY | 44.12% |
| 2021 | 558.27 Million CNY | -25.88% |
| 2020 | 753.21 Million CNY | 114.77% |
| 2019 | 350.71 Million CNY | -14.33% |
| 2018 | 409.39 Million CNY | 32.76% |
| 2017 | 308.36 Million CNY | -26.57% |
| 2016 | 419.97 Million CNY | -22.81% |
| 2015 | 544.09 Million CNY | 0.27% |
| 2014 | 542.64 Million CNY | 380.18% |
| 2013 | 113 Million CNY | 54.14% |
| 2012 | 73.31 Million CNY | 11.26% |
| 2011 | 65.89 Million CNY | -44.69% |
| 2010 | 119.15 Million CNY | 57.36% |
| 2009 | 75.72 Million CNY | 27.54% |
| 2008 | 59.37 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 685.98 Million CNY | 5.43% |
| 2024 Q3 | 695.74 Million CNY | 7.01% |
| 2024 Q2 | 650.19 Million CNY | -5.22% |
| 2023 Q2 | 490.3 Million CNY | -11.12% |
| 2023 Q3 | 457.59 Million CNY | -6.67% |
| 2023 FY | 650.66 Million CNY | -19.13% |
| 2023 Q1 | 551.63 Million CNY | -31.44% |
| 2023 Q4 | 650.66 Million CNY | 42.19% |
| 2022 Q2 | 578.12 Million CNY | 0.7% |
| 2022 FY | 804.56 Million CNY | 44.12% |
| 2022 Q4 | 804.56 Million CNY | 26.36% |
| 2022 Q3 | 636.71 Million CNY | 10.13% |
| 2022 Q1 | 574.1 Million CNY | 2.84% |
| 2021 Q1 | 950.57 Million CNY | 26.2% |
| 2021 Q3 | 538.83 Million CNY | -23.77% |
| 2021 Q4 | 558.27 Million CNY | 3.61% |
| 2021 Q2 | 706.86 Million CNY | -25.64% |
| 2021 FY | 558.27 Million CNY | -25.88% |
| 2020 Q4 | 753.21 Million CNY | -6.48% |
| 2020 Q1 | 717.55 Million CNY | 104.6% |
| 2020 FY | 753.21 Million CNY | 114.77% |
| 2020 Q3 | 805.38 Million CNY | -26.98% |
| 2020 Q2 | 1.1 Billion CNY | 53.71% |
| 2019 Q1 | 497.04 Million CNY | 21.41% |
| 2019 FY | 350.71 Million CNY | -14.33% |
| 2019 Q4 | 350.71 Million CNY | -4.81% |
| 2019 Q3 | 368.45 Million CNY | -26.12% |
| 2019 Q2 | 498.71 Million CNY | 0.34% |
| 2018 Q1 | 314.97 Million CNY | 2.14% |
| 2018 Q2 | 302.52 Million CNY | -3.95% |
| 2018 Q4 | 409.39 Million CNY | 31.34% |
| 2018 Q3 | 311.71 Million CNY | 3.04% |
| 2018 FY | 409.39 Million CNY | 32.76% |
| 2017 Q3 | 525.79 Million CNY | -36.95% |
| 2017 FY | 308.36 Million CNY | -26.57% |
| 2017 Q4 | 308.36 Million CNY | -41.35% |
| 2017 Q2 | 833.97 Million CNY | 7.84% |
| 2017 Q1 | 773.36 Million CNY | 84.15% |
| 2016 FY | 419.97 Million CNY | -22.81% |
| 2016 Q4 | 419.97 Million CNY | 56.23% |
| 2016 Q3 | 268.81 Million CNY | -12.17% |
| 2016 Q2 | 306.05 Million CNY | -34.91% |
| 2016 Q1 | 470.17 Million CNY | -13.59% |
| 2015 Q3 | 1 Billion CNY | 3.72% |
| 2015 Q2 | 972.89 Million CNY | 47.47% |
| 2015 Q1 | 659.72 Million CNY | 21.58% |
| 2015 Q4 | 544.09 Million CNY | -46.08% |
| 2015 FY | 544.09 Million CNY | 0.27% |
| 2014 FY | 542.64 Million CNY | 380.18% |
| 2014 Q2 | 282.66 Million CNY | 50.72% |
| 2014 Q4 | 542.64 Million CNY | 101.14% |
| 2014 Q3 | 269.78 Million CNY | -4.56% |
| 2014 Q1 | 187.53 Million CNY | 65.95% |
| 2013 Q4 | 113 Million CNY | 34.75% |
| 2013 FY | 113 Million CNY | 54.14% |
| 2013 Q2 | 111.09 Million CNY | 32.0% |
| 2013 Q3 | 83.86 Million CNY | -24.51% |
| 2013 Q1 | 84.16 Million CNY | 14.79% |
| 2012 Q3 | 77.95 Million CNY | -36.13% |
| 2012 Q1 | 192.85 Million CNY | 192.66% |
| 2012 Q2 | 122.05 Million CNY | -36.71% |
| 2012 FY | 73.31 Million CNY | 11.26% |
| 2012 Q4 | 73.31 Million CNY | -5.95% |
| 2011 Q3 | 102.29 Million CNY | -23.76% |
| 2011 Q4 | 65.89 Million CNY | -35.58% |
| 2011 Q2 | 134.16 Million CNY | 0.0% |
| 2011 FY | 65.89 Million CNY | -44.69% |
| 2010 FY | 119.15 Million CNY | 57.36% |
| 2010 Q4 | 119.15 Million CNY | 0.0% |
| 2009 FY | 75.72 Million CNY | 27.54% |
| 2008 FY | 59.37 Million CNY | 0.0% |